Do We Need Gadolinium-Based Contrast Agents for Routine MRI Surveillance of Unoperated Pituitary Macroadenoma?

References

1. 1.↵
   1. Ezzat S,
   2. Asa SL,
   3. Couldwell WT, et al

   . The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613–19 doi:10.1002/cncr.20412 pmid:15274075

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Aljabri KS,
   2. Bokhari SA,
   3. Assiri FY, et al

   . The epidemiology of pituitary adenomas in a community-based hospital: a retrospective single center study in Saudi Arabia. Ann Saudi Med 2016;36:341–45 doi:10.5144/0256-4947.2016.341 pmid:27710986

   CrossRefPubMed
3. 3.↵
   1. Hussein SH,
   2. Wahedi TS,
   3. Johani NA, et al

   . Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia. Hormones (Athens) 2018;17:261–67 doi:10.1007/s42000-018-0030-8 pmid:29858852

   CrossRefPubMed
4. 4.↵
   Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. 2021: American College of Radiology. 2021. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf.
5. 5.↵
   1. Granata V,
   2. Cascella M,
   3. Fusco R, et al

   . Immediate adverse reactions to gadolinium-based MR contrast media: a retrospective analysis on 10,608 examinations. Biomed Res Int 2016;2016:3918292 doi:10.1155/2016/3918292 pmid:27652261

   CrossRefPubMed
6. 6.↵
   1. Stojanov D,
   2. Aracki-Trenkic A,
   3. Benedeto-Stojanov D

   . Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents: current status. Neuroradiology 2016;58:433–41 doi:10.1007/s00234-016-1658-1 pmid:26873830

   CrossRefPubMed
7. 7.↵
   1. Kanda T,
   2. Ishii K,
   3. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
8. 8.↵
   1. Kanda T,
   2. Osawa M,
   3. Oba H, et al

   . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

   CrossRefPubMed
9. 9.↵
   1. Quattrocchi CC,
   2. Mallio CA,
   3. Errante Y, et al

   . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50:470–72 doi:10.1097/RLI.0000000000000154 pmid:25756685

   CrossRefPubMed
10. 10.↵
    1. Gulani V,
    2. Calamante F,
    3. Shellock FG

    , et al; International Society for Magnetic Resonance in Medicine. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017;16:564–70 doi:10.1016/S1474-4422(17)30158-8 pmid:28653648

    CrossRefPubMed
11. 11.↵
    1. Knosp E,
    2. Steiner E,
    3. Kitz K, et al

    . Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610–17; discussion 617–18 doi:10.1227/00006123-199310000-00008 pmid:8232800

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Koo TK,
    2. Li MY

    . A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016;15:155–63 doi:10.1016/j.jcm.2016.02.012 pmid:27330520

    CrossRefPubMed
13. 13.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Levy MJ,
    2. Robertson IJ,
    3. Khalk N, et al

    . Long-term follow-up of a large prospective cohort of patients with nonfunctioning pituitary adenomas: the outcome of a conservative management policy. Clin Endocrinol (Oxf) 2018;89:354–59 doi:10.1111/cen.13791 pmid:29920729

    CrossRefPubMed
15. 15.↵
    1. Ogiwara T,
    2. Nagm A,
    3. Nakamura T, et al

    . Significance and indications of surgery for asymptomatic nonfunctioning pituitary adenomas. World Neurosurg 2019;128:e752–59 doi:10.1016/j.wneu.2019.04.250 pmid:31077893

    CrossRefPubMed
16. 16.↵
    1. Molitch ME

    . Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 2009;23:667–75 doi:10.1016/j.beem.2009.05.001 pmid:19945030

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Kim JH,
    2. Dho YS,
    3. Kim YH, et al

    . Developing an optimal follow-up strategy based on the natural history of nonfunctioning pituitary adenomas. J Neurosurg 2019;131:500–06 doi:10.3171/2018.4.JNS172148 pmid:30215565

    CrossRefPubMed
18. 18.↵
    1. Dekkers OM,
    2. Pereira AM,
    3. Romijn JA

    . Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008;93:3717–26 doi:10.1210/jc.2008-0643 pmid:18682516

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Ajlan A,
    2. Achrol AS,
    3. Albakr A, et al

    . Cavernous sinus involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endonasal resection. J Neurol Surg B Skull Base 2017;78:273–82 doi:10.1055/s-0036-1598022 pmid:28603683

    CrossRefPubMed
20. 20.↵
    1. Woodworth GF,
    2. Patel KS,
    3. Shin B, et al

    . Surgical outcomes using a medial-to-lateral endonasal endoscopic approach to pituitary adenomas invading the cavernous sinus. J Neurosurg 2014;120:1086–94 doi:10.3171/2014.1.JNS131228 pmid:24527820

    CrossRefPubMed
21. 21.↵
    1. Fahlbusch R,
    2. Honegger J,
    3. Buchfelder M

    . Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992;21:669–92 doi:10.1016/S0889-8529(18)30208-1 pmid:1521518

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Powell M

    . Recovery of vision following transsphenoidal surgery for pituitary adenomas. Br J Neurosurg 1995;9:367–73 doi:10.1080/02688699550041377 pmid:7546358

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Hisanaga S,
    2. Kakeda S,
    3. Yamamoto J, et al

    . Pituitary macroadenoma and visual impairment: postoperative outcome prediction with contrast-enhanced FIESTA. AJNR Am J Neuroradiol 2017;38:2067–72 doi:10.3174/ajnr.A5394 pmid:28912278

    Abstract/FREE Full Text
24. 24.↵
    1. Boto J,
    2. Guatta R,
    3. Fitsiori A, et al

    . Is contrast medium really needed for follow-up MRI of untreated intracranial meningiomas? AJNR Am J Neuroradiol 2021;42:1421–28 doi:10.3174/ajnr.A7170 pmid:34117017

    Abstract/FREE Full Text
25. 25.↵
    1. Buch K,
    2. Juliano A,
    3. Stankovic KM, et al

    . Noncontrast vestibular schwannoma surveillance imaging including an MR cisternographic sequence: is there a need for postcontrast imaging? J Neurosurg 2018;131:549–54 doi:10.3171/2018.3.JNS1866 pmid:30095338

    CrossRefPubMed